Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company dedicated to the treatment and prevention of cancer. The company's core focus includes developing vaccines and therapies aimed at critical unmet needs in oncology. Anixa's innovative approach involves both diagnostics and therapeutics to detect and treat cancer at its most curable stages.
The company's therapeutic portfolio features a pioneering ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center. This program utilizes a novel CAR-T technology, known as chimeric endocrine receptor T-cell (CER-T), which targets the follicle-stimulating hormone receptor (FSHR) specifically expressed on ovarian cells. This technology represents a potential breakthrough in treating solid tumors, a challenge for traditional CAR-T therapies.
Anixa is also advancing a unique vaccine portfolio in collaboration with Cleveland Clinic, targeting the prevention of breast cancer, specifically triple-negative breast cancer (TNBC), the most aggressive form of the disease, as well as ovarian cancer. These vaccine technologies focus on immunizing against
On March 2, 2023, Anixa Biosciences (NASDAQ: ANIX) announced that its CEO, Dr. Amit Kumar, will present a corporate update at the company’s 2023 Annual Meeting of Stockholders on March 9 at 10:00 AM PST. The meeting will be virtual and accessible to shareholders and other interested parties via this link. Anixa focuses on developing treatments for cancer and infectious diseases, with collaborations involving cutting-edge technologies in cancer immunotherapy and COVID-19 therapeutics. The company emphasizes its unique business model of partnering with renowned research institutions.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent broadening the protection of its breast cancer vaccine technology. This patent, titled "Vaccine Adjuvants and Formulations," was developed at the Cleveland Clinic, making Anixa the exclusive licensee. The breast cancer vaccine targets Triple Negative Breast Cancer (TNBC), a particularly lethal form, and is currently in Phase 1 clinical trials. Data from these trials is expected to be presented at the American Association for Cancer Research annual meeting in April.
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology firm focused on cancer treatment and prevention, announced the formation of its Breast Cancer Clinical Advisory Board. This board comprises leading experts who will assist in the development of clinical plans for Anixa's breast cancer vaccine, currently in Phase 1 trials. CEO Amit Kumar emphasized that collaboration with these specialists will enhance the planning and execution of future trials. The vaccine targets proteins present in triple-negative breast cancers, potentially providing preemptive immune protection against emerging tumors.
Anixa Biosciences (NASDAQ: ANIX) announced its participation in the Biotech Showcase 2023 conference, taking place from January 9-11, 2023, in San Francisco. The company will present on January 9 at 3:30 PM PST, providing updates on its clinical programs and corporate achievements. Anixa, focused on cancer and infectious diseases, aims to leverage collaborations with leading research institutions to advance its innovative therapies, including vaccines for breast and ovarian cancers and novel CAR-T treatments.
Anixa Biosciences (NASDAQ: ANIX) announced that its Phase 1a trial for a preventative breast cancer vaccine has reached the maximum tolerated dose (MTD). This milestone is crucial for evaluating the vaccine's safety and immune response in women at risk for breast cancer. The study is being conducted in collaboration with Cleveland Clinic and involves participants diagnosed with triple-negative breast cancer. Future phases will guide dosing based on the MTD, with complete immunological results expected by Q2 2023.
Anixa Biosciences (NASDAQ: ANIX) announced a presentation regarding its ongoing breast cancer vaccine trial at the 2022 San Antonio Breast Cancer Symposium on December 7, 2022. The presentation, titled Phase I trial of an alpha-lactalbumin vaccine in patients with operable triple-negative breast cancer (TNBC), highlights the trial's design and aims to activate the immune response against a protein expressed in most TNBC cases. Anixa emphasizes its innovative approach in cancer immunotherapy, focusing on prevention through its vaccine technologies.
On October 31, 2022, Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Jose Conejo-Garcia, the inventor of its ovarian cancer CAR-T technology, will be the keynote speaker at Duke Cancer Institute's Immuno-Oncology Research Program Retreat on November 4, 2022. Dr. Conejo-Garcia will present on the CAR-T technology, which targets the follicle stimulating hormone receptor (FSHR) in ovarian cancer and is undergoing a Phase 1 clinical trial. This innovative approach is part of Anixa's broader mission to develop cutting-edge therapies for cancer and infectious diseases.
Anixa Biosciences, Inc. (NASDAQ: ANIX) has initiated a Phase 1b trial for its preventive breast cancer vaccine at Cleveland Clinic, focusing on safety and immune response. The study, funded by the U.S. Department of Defense, is recruiting high-risk cancer-free participants who will receive three vaccinations over six weeks. This follows a Phase 1a trial with promising results, encouraging the company to advance earlier than planned. The trial aims to tackle triple-negative breast cancer, known for its lethality, with completion expected by the end of 2023.
Anixa Biosciences (NASDAQ: ANIX) announced a presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting on its ovarian cancer CAR-T therapy trial. Scheduled for November 10, 2022, at 9:00 AM EST, the presentation will be led by Dr. Robert Wenham from Moffitt Cancer Center. The trial focuses on genetically engineered T-cells targeting the follicle-stimulating hormone receptor in recurrent ovarian cancer patients. Anixa is advancing various therapeutic programs, including collaborations for COVID-19 and breast cancer vaccines.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced Dr. Jose Conejo-Garcia will present at the Rivkin Center and the American Association for Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium on September 28, 2022. He will discuss the company's ovarian cancer CAR-T technology, targeting follicle-stimulating hormone receptors on ovarian granulosa cells. The ongoing Phase 1 clinical trial has successfully treated its first patient, potentially transforming ovarian cancer treatment. Anixa collaborates with Moffitt Cancer Center on this innovative approach.
FAQ
What is the current stock price of Anixa Biosciences (ANIX)?
What is the market cap of Anixa Biosciences (ANIX)?
What does Anixa Biosciences specialize in?
What are the key components of Anixa's therapeutic portfolio?
What recent achievements has Anixa Biosciences announced?
Who are some of Anixa Biosciences' key collaborators?
How does Anixa's CER-T technology differ from traditional CAR-T therapies?
What is unique about Anixa's cancer vaccine technology?
Which forms of cancer are Anixa's vaccines targeting?
What are some recent clinical trial results from Anixa?
Does Anixa Biosciences participate in industry conferences?
Where can I find more information about Anixa Biosciences?
